Alteogen
Biosimilar developer, South Korea. 1 development product across 1 molecule: aflibercept.
Portfolio by market
| Molecule | Product | FDA | EMA | MHRA | PMDA | HC | CDSCO | EDE | Markets |
|---|---|---|---|---|---|---|---|---|---|
| Aflibercept | Eyluxvi ALT-L9 | · | Sep 2025 | · | · | · | · | · | 1/7 |
Month shown is the first approval or registration of that product in that market.
In development
ClinicalTrials.gov lists one comparative trial sponsored by Alteogen for one molecule: trastuzumab. Candidates without an approval yet in the seven markets: ALT02.
| Molecule | Candidate | Developer or sponsor | Reference product | Phase | Design | Registry status | Started | Primary completion | In the Atlas | Registry record |
|---|---|---|---|---|---|---|---|---|---|---|
| Trastuzumab | ALT02 | Alteogen | Herceptin | Phase 1 | Comparative PK | Completed | Feb 2016 | Aug 2016 | no approval in the seven markets | NCT03242239 |
Registry data from ClinicalTrials.gov, entered by the sponsors and not verified by any regulator. Status and dates are as posted; sponsors often update them late. Trials registered only on other registries, such as India's CTRI or China's ChiCTR, are not included. Checked 12 Sep 2026.
Companies on the same molecules
Developers whose portfolios overlap most with Alteogen, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.
Chronology
- EMASep 2025Eyluxvi, aflibercept
Compare Alteogen with other developers on the comparison page.
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant